Institution Directory

Clinical trials at UCSF

Sites in San Francisco, CA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 2:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1396

Shown on this page

Current sort

Live official records

Conditions: Pancreas Cancer, Pancreas Cyst, Pancreatic Ductal Adenocarcinoma, Genetic Predisposition
Interventions: Not listed
Lead sponsor: Arbor Research Collaborative for Health; Other
Eligibility: 18 Years to 90 Years
Enrollment: 20,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2030
U.S. locations: 45
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Burbank, California + 38 more

Conditions: Breast Neoplasms
Interventions: pembrolizumab, paclitaxel, nab-paclitaxel, liposomal doxorubicin, capecitabine, normal saline, dextrose; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 342 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 41
States / cities: Birmingham, Alabama • Tucson, Arizona • Monterey, California + 33 more

Conditions: Urothelial Carcinoma
Interventions: disitamab vedotin, pembrolizumab, gemcitabine, cisplatin, carboplatin; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 412 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 89
States / cities: Gilbert, Arizona • Alhambra, California • Arcadia, California + 46 more

Conditions: Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms, Metastatic Breast Cancer, Metastatic Gastric Cancer, Advanced Breast Cancer, Advanced Gastric Cancer
Interventions: disitamab vedotin, tucatinib; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 77
States / cities: Tucson, Arizona • Orange, California • San Francisco, California + 39 more

Conditions: Biliary Tract Cancer, Metastatic Cancer, Advanced Cancer
Interventions: Ramucirumab, Merestinib, Cisplatin, Gemcitabine, Placebo Oral, Placebo IV; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 13
States / cities: Tucson, Arizona • San Francisco, California • Washington D.C., District of Columbia + 7 more

Conditions: Urothelial Carcinoma
Interventions: disitamab vedotin, pembrolizumab; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 372 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 158
States / cities: Gilbert, Arizona • Anaheim, California • Arcadia, California + 96 more

Conditions: Interstitial Lung Disease, Common Variable Immunodeficiency
Interventions: Abatacept, Placebo; Drug · Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 4 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 6
States / cities: San Francisco, California • Tampa, Florida • Burlington, Massachusetts + 3 more

Conditions: Surgical Site Infection
Interventions: 4% Chlorhexidine Gluconate, 2% Mupirocin, Soap Without Antiseptic Properties (Placebo), Placebo Nasal Ointment; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 2,700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 4
States / cities: Newport Beach, California • Orange, California • Sacramento, California + 1 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Zilucoplan, Verdiperstat, CNM-Au8, Pridopidine, SLS-005 Trehalose, ABBV-CLS-7262, DNL343, NUZ-001; Drug
Lead sponsor: Merit E. Cudkowicz, MD; Other
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 81
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 66 more

Conditions: Neuroblastoma
Interventions: Universal Donor (UD) TGFβi NK Cells, Temozolomide, Irinotecan, Dinutuximab, GM-CSF; Drug
Lead sponsor: New Approaches to Neuroblastoma Therapy Consortium; Other
Eligibility: 1 Year to 31 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2038
U.S. locations: 13
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more

Conditions: Breast Cancer
Interventions: Vinorelbine, Trastuzumab, Avelumab, Utomilumab; Drug
Lead sponsor: Adrienne G. Waks; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 17
States / cities: Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 12 more

Conditions: Relapsed/Refractory Peripheral T-Cell Lymphoma, Adult T Cell Leukemia/Lymphoma
Interventions: Valemetostat Tosylate; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 14
States / cities: Duarte, California • Palo Alto, California • San Francisco, California + 10 more

About this UCSF institution page

What this page lists: ClinicalTrials.gov records that list UCSF in San Francisco, CA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at UCSF

Filter and sort this campus

Live official records

Pancreatic Cancer Early Detection Consortium

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease

Decolonization to Reduce After-Surgery Events of Surgical Site Infection

HEALEY ALS Platform Trial - Master Protocol

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

About this UCSF institution page